Association of deficiency in antibody response to vaccine and heterogeneity of Ehrlichia risticii strains with Potomac horse fever vaccine failure in horses.
Abstract: Ehrlichia risticii is the causative agent of Potomac horse fever (PHF), which continues to be an important disease of horses. Commercial inactivated whole-cell vaccines are regularly used for immunization of horses against the disease. However, PHF is occurring in large numbers of horses in spite of vaccination. In a limited study, 43 confirmed cases of PHF occurred between the 1994 and 1996 seasons; of these, 38 (89%) were in horses that had been vaccinated for the respective season, thereby clearly indicating vaccine failure. A field study of horses vaccinated with two PHF vaccines indicated a poor antibody response, as determined by immunofluorescence assay (IFA) titers. In a majority of horses, the final antibody titer ranged between 40 and 1,280, in spite of repeated vaccinations. None of the vaccinated horses developed in vitro neutralizing antibody in their sera. Similarly, one horse experimentally vaccinated three times with one of the vaccines showed a poor antibody response, with final IFA titers between 80 and 160. The horse did not develop in vitro neutralizing antibody or antibody against the 50/85-kDa strain-specific antigen (SSA), which is the protective antigen of the original strain, 25-D, and the variant strain of our laboratory, strain 90-12. Upon challenge infection with the 90-12 strain, the horse showed clinical signs of the disease. The horse developed neutralizing antibody and antibody to the 50/85-kDa SSA following the infection. Studies of the new E. risticii isolates from the field cases indicated that they were heterogeneous among themselves and showed differences from the 25-D and 90-12 strains as determined by IFA reactivity pattern, DNA amplification finger printing profile, and in vitro neutralization activity. Most importantly, the molecular sizes of the SSA of these isolates varied, ranging from 48 to 85 kDa. These studies suggest that the deficiency in the antibody response to the PHF vaccines and the heterogeneity of E. risticii isolates may be associated with the vaccine failure.
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research article examines the ineffectiveness of vaccines used in combating Potomac horse fever (PHF) in horses due to the deficiency in antibody response to the vaccines and the inconsistencies of the Ehrlichia risticii (causative pathogen) strains.
Research Overview
The research was instigated by the observation that a large number of horses were contracting PHF even though they had been vaccinated against the disease. To quantify this, a study was conducted between 1994 and 1996, where it was found that 89% of the confirmed PHF cases were in horses that had been vaccinated for the respective season.
The study was then extended to the horses vaccinated with two types of PHF vaccines, where it was found that these vaccines induced a poor antibody response as was determined by immunofluorescence assay (IFA) titers.
An experimental horse was given vaccinations three times, but it showed a poor antibody response and did not develop neutralizing antibodies. When the horse was infected with a strain of E. risticii, it presented PHF clinical signs, further demonstrating the vaccine’s failure.
Vaccine Failure and Antibody Response
The study discovered that none of the vaccinated horses developed in vitro neutralizing antibody in their sera – this suggests that the vaccines were failing to stimulate an effective immune response.
There was an observed poor antibody response – the final antibody titer ranged from 40 to 1,280, despite repeated vaccinations.
The experimentally vaccinated horse also showed a deficient antibody response and did not develop any neutralizing antibody. However, this horse developed the neutralizing antibody after being infected with the E. risticii strain, indicating that the disease triggered the appropriate antibody response.
Heterogeneity of Ehrlichia risticii Strains
New E. risticii isolates from the field cases were found to be variable and different from the original strain used for the vaccines.
The differences were seen in the IFA reactivity pattern, DNA amplification fingerprinting profile, and in vitro neutralization activity.
Interestingly, the molecular sizes of the strain-specific antigen (SSA) of these isolates varied, ranging from 48 to 85 kDa. The SSAs are the protective antigens.
Conclusion
The research concludes that the deficiency in antibody response and the diversity of the E. risticii strains may be associated with the observed vaccine failure. This suggests a need to adapt the vaccines to be more effective against the disease.
Cite This Article
APA
Dutta SK, Vemulapalli R, Biswas B.
(1998).
Association of deficiency in antibody response to vaccine and heterogeneity of Ehrlichia risticii strains with Potomac horse fever vaccine failure in horses.
J Clin Microbiol, 36(2), 506-512.
https://doi.org/10.1128/JCM.36.2.506-512.1998
Biswas B. Molecular basis of antigenic variation of strain-specific surface antigen gene of Ehrlichia risticii and development of a multiplex PCR assay for differentiation of strains. Ph.D. Dissertation. College Park: University of Maryland; 1996.
Dutta SK, Shankarappa B, Thaker SR, Mattingly-Napier BL. DNA restriction endonuclease cleavage pattern and protein antigen profile of Ehrlichia risticii.. Vet Microbiol 1990 Oct;25(1):29-38.
Dutta S K, Shakarappa B, Mattingly-Napier B L. Antigenic analysis of Ehrlichia risticii isolates. Equine infectious Diseases VI Cambridge, England: R&W Publication Ltd.; 1991. pp. 61–65.
Holland C J, Weiss E, Burgdorfer W, Cole A I, Kakoma I. Ehrlichia risticii sp. nov.: etiological agent of equine monocytic ehrlichiosis (synonym, Potomac horse fever). Int J Syst Bacteriol 1985;35:524–526.
Rhabach B W, Breider M A, Gerhardt R R, Henton J E. The characteristic, treatment, and control of equine monocytic ehrlichiosis. Vet Med 1993;88:448–451.
Rikihisa Y, Jiang BM. Effect of antibiotics on clinical, pathologic and immunologic responses in murine Potomac horse fever: protective effects of doxycycline.. Vet Microbiol 1989 Mar;19(3):253-62.
Vemulapalli R, Biswas B, Dutta SK. Studies with recombinant proteins of Ehrlichia risticii: identification of strain-specific antigen as a protective antigen.. Vet Parasitol 1998 Apr 15;76(3):189-202.
Vidor E, Bissul G, Moreau Y, Madec J L, Cador J L. Serologie positive a Ehrlichia risticii chez une jument presentant un tableau d’ehrlichiose equine. Pratique Vet Equine 1988;20:5–10.
Whitlock R J, Palmer J E, Meinersman R J, Crane S A. Evaluation of an experimental vaccine for Potomac horse fever. Proceedings of the Symposium on Potomac Horse Fever, 1987 1987; pp. 61–62.
Lin M, Bachman K, Cheng Z, Daugherty SC, Nagaraj S, Sengamalay N, Ott S, Godinez A, Tallon LJ, Sadzewicz L, Fraser C, Dunning Hotopp JC, Rikihisa Y. Analysis of complete genome sequence and major surface antigens of Neorickettsia helminthoeca, causative agent of salmon poisoning disease. Microb Biotechnol 2017 Jul;10(4):933-957.
Rikihisa Y, Zhang C, Kanter M, Cheng Z, Ohashi N, Fukuda T. Analysis of p51, groESL, and the major antigen P51 in various species of Neorickettsia, an obligatory intracellular bacterium that infects trematodes and mammals. J Clin Microbiol 2004 Aug;42(8):3823-6.
Kanter M, Mott J, Ohashi N, Fried B, Reed S, Lin YC, Rikihisa Y. Analysis of 16S rRNA and 51-kilodalton antigen gene and transmission in mice of Ehrlichia risticii in virgulate trematodes from Elimia livescens snails in Ohio. J Clin Microbiol 2000 Sep;38(9):3349-58.